Why I’m avoiding these 3 FTSE 100 stocks in 2020

G A Chester sees different issues with these three FTSE 100 (INDEXFTSE:UKX) stocks, but valuations are the acid test.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are a number of FTSE 100 stocks I think could disappoint investors in 2020. Among them are AstraZeneca (LSE: AZN), St. James’s Place (LSE: STJ) and Scottish Mortgage Investment Trust (LSE: SMT). Here’s why I’m avoiding these three.

Dubious core strength

AstraZeneca’s management has maintained the core earnings per share (EPS) guidance it gave at the start of the year of $3.50-$3.70 for 2019. At the midpoint and current exchange rates, this gives a price-to-earnings (P/E) ratio of 26.5 at a share price of 7,300p.

This is a huge premium to Footsie pharma peers GlaxoSmithKline and Hikma Pharmaceuticals, which trade at P/Es of 14.4 and 17.7 respectively. Furthermore, I’d argue AZN’s core EPS, on which the 26.5 P/E is based, grossly overstates its real core earnings, and that the true P/E is nearer a jaw-dropping 40.

This is because I exclude one-off profits from the divestment of non-core assets, which can’t go on forever but which AZN books as core operating profit. I also include legal costs (a routine expense in operating a big pharma company), which AZN excludes. AZN looks overvalued to me on its own core EPS measure, but grossly overvalued on what I consider its true core earnings.

Iffy business model

I’m avoiding wealth manager St. James’s Place on a view that it’s not only overvalued, but also has an iffy business model, and will have to change, with profit-margin-sapping consequences.

At a share price of around 1,100p, STJ’s P/E is 32.4 on forecast EPS of 34p for 2019. This earnings multiple is far too high, in my opinion. Furthermore, a valuation of more than 3% of funds under management (FUM) has proved a trusty indicator of overvaluation, in my experience. With a market capitalisation of £5.88bn, and FUM of £112.82bn, STJ is valued at 5.2% of FUM.

The company’s management fees and exit fees are excessive, in my view. Investors haven’t worried too much about this, seeing their portfolios increase in value over the last 10 years of rising markets, but are likely to pay a lot more attention in a downturn. Furthermore, with investors generally becoming a lot savvier about the corrosive effect of fees on returns, I think STJ will ultimately have to reset its margins.

Bonkers

It’s a peculiar and persistent feature of the UK stock market that some investment trust or another will rise from the FTSE 250 to the FTSE 100. However, no trust in history has gained sufficient critical mass to maintain its position in the top index.

Scottish Mortgage is the current representative in the FTSE 100. It’s achieved its status by a combination of high returns (471% over the last 10 years) and increasing popularity with investors (taking its shares to a premium to net asset value (NAV)).

The company has surfed on the outperformance of the US market and tech sector, holding a number of the so-called FAANG stocks, and the likes of Illumina and Tesla. The managers of the trust have borrowed money to gear returns (gearing is currently 9%), and remain optimistic on the outlook.

Personally, I think the valuations of many of the underlying holdings are bonkers. I fear a de-rating, SMT’s NAV dropping, gearing working negatively, and the shares moving to a wide discount to NAV. If so, SMT will become another in the long history of investment trusts failing to maintain a place in the FTSE 100.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline and Tesla. The Motley Fool UK has recommended AstraZeneca and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

Will Lloyds shares rise 25% or 39% by this time next year?

Lloyds shares are expected to rebound after sinking to fresh multi-month peaks. Royston Wild considers the outlook for the FTSE…

Read more »

Modern suburban family houses with car on driveway
Investing Articles

£7,500 invested in Taylor Wimpey shares 18 months ago is now worth…

A raft of issues have been plaguing the housebuilding sector in the last year-and-a-half. How bad was the damage for…

Read more »

A rear view of a female in a bright yellow coat walking along the historic street known as The Shambles in York, UK which is a popular tourist destination in this Yorkshire city.
Investing Articles

£210 drip-fed into this 6.8%-yielding UK stock could lead to a £1,000 second income 

This FTSE 100 dividend stock has slumped nearly 11% inside two weeks, making it a worthy candidate to consider for…

Read more »

ISA Individual Savings Account
Investing Articles

ISA or SIPP? 2 factors to consider

As next month's ISA contribution deadline creeps up, our writer considers a couple of key differences between using a SIPP,…

Read more »

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing Articles

Is this 5.6% yielding dividend share a brilliant defensive bolthole as war rages?

Harvey Jones looks at a FTSE 100 dividend share with a brilliant record of delivering income and growth, and wonders…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

2 quality UK stocks trading below intrinsic value?

UK stocks have a reputation for being cheap, but could value investors be in dreamland with the opportunities being presented…

Read more »

Businessman with tablet, waiting at the train station platform
Investing Articles

£15,000 put into Greggs shares a year ago is worth this much now…

Greggs' sausage rolls may be tasty enough -- but its shares have left a bad taste in some investors' mouths…

Read more »

Investing Articles

FTSE 100 drops sharply — are serious bargains emerging in UK stocks?

Andrew Mackie looks at the FTSE 100 and explores how sharp falls, market volatility, and structural opportunities are reshaping the…

Read more »